409 related articles for article (PubMed ID: 15870145)
1. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
[TBL] [Abstract][Full Text] [Related]
2. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
[TBL] [Abstract][Full Text] [Related]
3. Quality of care for gout in the US needs improvement.
Singh JA; Hodges JS; Toscano JP; Asch SM
Arthritis Rheum; 2007 Jun; 57(5):822-9. PubMed ID: 17530682
[TBL] [Abstract][Full Text] [Related]
4. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
5. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
Banse C; Fardellone P; Paccou J
Joint Bone Spine; 2014 Oct; 81(5):461-2. PubMed ID: 24703403
[No Abstract] [Full Text] [Related]
7. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.
Mikuls TR; Curtis JR; Allison JJ; Hicks RW; Saag KG
J Rheumatol; 2006 Mar; 33(3):562-6. PubMed ID: 16482645
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
9. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
Roddy E; Zhang W; Doherty M
Ann Rheum Dis; 2007 Oct; 66(10):1311-5. PubMed ID: 17504843
[TBL] [Abstract][Full Text] [Related]
10. Allopurinol adherence among patients with gout: an Italian general practice database study.
Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol initiation and all-cause mortality in the general population.
Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK
Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118
[TBL] [Abstract][Full Text] [Related]
13. Colchicine prescribing and safety monitoring in patients with gout.
Ly J; Gow P; Dalbeth N
N Z Med J; 2007 Nov; 120(1265):U2808. PubMed ID: 18264188
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
15. Utilization of allopurinol in the Australian community.
Chung Y; Lu CY; Graham GG; Mant A; Day RO
Intern Med J; 2008 Jun; 38(6):388-95. PubMed ID: 18422564
[TBL] [Abstract][Full Text] [Related]
16. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
[TBL] [Abstract][Full Text] [Related]
17. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
18. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat: a new treatment for hyperuricaemia in gout.
Edwards NL
Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
[TBL] [Abstract][Full Text] [Related]
20. [Hyperuricemia, gout, pseudogout and concomitant diseases].
Schmidt BM; Wagner AD
Dtsch Med Wochenschr; 2011 Dec; 136(48):2489-91. PubMed ID: 22109583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
